2017
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
Alvarado D, Ligon GF, Lillquist JS, Seibel SB, Wallweber G, Neumeister VM, Rimm DL, McMahon G, LaVallee TM. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC. PLOS ONE 2017, 12: e0181356. PMID: 28723928, PMCID: PMC5517012, DOI: 10.1371/journal.pone.0181356.Peer-Reviewed Original ResearchConceptsNeuregulin-1NRG1 expressionErbB3 activationNeck squamous cell carcinomaSquamous cell carcinomaEnhanced anti-tumor activitySubset of HNSCCUnmet medical needHNSCC cell linesHNSCC patient samplesAnti-tumor activityGrowth factor αLigand neuregulin-1Cell carcinomaEGFR/ErbB familyHNSCC modelsCetuximab treatmentErbB receptor inhibitionReceptor inhibitionReceptor levelsRespective signaling pathwaysSolid tumorsTumor typesHNSCCPotential biomarkers
2007
Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis
Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia‐Dąbrowska N, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt SM, García‐Closas M. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis. International Journal Of Cancer 2007, 121: 1079-1085. PMID: 17487843, DOI: 10.1002/ijc.22812.Peer-Reviewed Original ResearchConceptsBody mass indexPostmenopausal womenEtiologic factorsHER2 levelsPremenopausal womenOdds ratioER alphaBreast cancer hormone receptor statusPopulation-based case-control studyBreast Cancer Hormone ReceptorsHormone receptor statusCase-control studyPopulation-based analysisPathologic characteristicsPR statusReceptor statusMass indexER betaClinical recordsMarker levelsHER2 expressionLarge tumorsBreast cancerReceptor levelsTumor features